Biotechnology Industry - Publications - Faculty & Research - Harvard Business School

Filter Results: (482)

Filter Results: (482)

Show Results For

← Page 5 of 482 Results →

October 2001 (Revised April 2002)
Case

Calgene, Inc.

By: Ray A. Goldberg and John T. Gourville

In 1993, Calgene is on the verge of introducing the world's first genetically engineered plant product--a tomato will taste better and stay fresh longer. At the same time, it is using biotechnology to produce improved plant products for the cottonseed and the... View Details

Keywords: Information Technology; Marketing Strategy; Market Entry and Exit; Product Launch; Innovation Strategy; Social Issues; Production; Problems and Challenges; Biotechnology Industry; Biotechnology Industry

October 2002
Case

A Father's Love: Novazyme Pharmaceuticals, Inc.

By: Richard M.J. Bohmer and Bradley Campbell

John Crowley, CEO of Novazyme Pharmaceuticals, a start-up biotechnology firm developing an orphan drug to treat a rare lysosomal storage disorder from which his children suffer, must choose between a partnership and a buyout to have sufficient funds and support to get... View Details

Keywords: Technological Innovation; Business Startups; Partners and Partnerships; Financing and Loans; Governing Rules, Regulations, and Reforms; Sales; Price; Product Development; Motivation and Incentives; Decision Choices and Conditions; Biotechnology Industry; Biotechnology Industry

13 Jan 2003
Research & Ideas

Making Biotech Work as a Business

create safer and more effective treatments and, of course, reap profits—industry executives, like hopeful patients, still restlessly wait for relief. Given its scientific potential, said Pisano, biotech continues to bump against several economic barriers that need to... View Details

Keywords: by Martha Lagace; Biotechnology; Biotechnology; Biotechnology

2006
Book

Science Business: The Promise, the Reality, and the Future of Biotech

By: Gary P. Pisano

Why has the biotechnology industry failed to perform up to expectations—despite all its promise? In Science Business, Gary P. Pisano answers this question by providing an incisive critique of the industry. Pisano not only reveals the underlying causes of... View Details

Keywords: Science; Business Ventures; Biotechnology Industry

Find at Harvard

March 2022
Case

Tensions at SearchLight Cures

By: Laura Huang and Sarah Mehta

This general experience case tells the story of SearchLight Cures, a fictional biotechnology startup. Having discovered a new therapy for a rare disease, the company’s co-founders find themselves at an impasse over a pricing disagreement. View Details

Keywords: Business Ventures; Business Growth and Maturation; Business Startups; Communication; Interpersonal Communication; Values and Beliefs; Management; Negotiation; Relationships; Partners and Partnerships; Science; Biotechnology Industry; United States; California; San Francisco

October 2001 (Revised May 2002)
Case

Proteome Systems Limited

A Sydney-based biotechnology company is attempting to enter the fast-growing proteomics area. This case highlights choices in business design and changes in these over time. Also addresses issues in geographic location. View Details

Keywords: Organizational Change and Adaptation; Geographic Location; Market Entry and Exit; Biotechnology Industry; Sydney

September 2020 (Revised January 2021)
Case

Catalys Pacific

By: Joshua Lev Krieger

In 2019, BT Slingsby founds Catalys Pacific, the first biotech “venture creation” fund in Tokyo. After convincing some of the biggest Japanese pharmaceutical firms to invest, BT hopes the fund can make a big splash and transform biotechnology innovation in Japan. After... View Details

Keywords: Pharmaceutical Companies; Biotech; Health Care; Entrepreneur; Innovation; International Business; Entrepreneurial Finance; Entrepreneurship; Finance; Innovation Strategy; Venture Capital; Strategy; Cross-Cultural and Cross-Border Issues; Pharmaceutical Industry; Pharmaceutical Industry; Tokyo

September 2019
Case

Nimbus Therapeutics

By: Peter Barrett, Karim Lakhani and Julia Kelley

This case focuses on Nimbus Therapeutics, a biotechnology startup based in Cambridge, Massachusetts, as its leadership team tries to determine the company’s long-term strategy. The startup’s founders structured Nimbus as a limited liability company, which has given it... View Details

Keywords: Business Startups; Organizational Structure; Strategy; Biotechnology Industry

February 2010 (Revised September 2011)
Case

Roche's Acquisition of Genentech

By: Carliss Y. Baldwin, Bo Becker and Vincent Marie Dessain

Franz Humer, CEO of the Roche Group, must decide whether to mount a hostile tender offer for the publicly-owned shares of Roche's biotechnology subsidiary, Genentech. The case provides opportunities to analyze Roche's strategy with respect to Genentech, the pros and... View Details

Keywords: Mergers and Acquisitions; Business Subsidiaries; Negotiation Offer; Organizational Culture; Corporate Strategy; Biotechnology Industry; Biotechnology Industry; Switzerland

June 1997 (Revised October 2001)
Case

Elliot Lebowitz

By: Paul A. Gompers and Alexander Tsai

Elliot Lebowitz, president and CEO of BioTransplant, must decide on a strategy for this young biotechnology start-up. Among the issues to be resolved are focus of research and search for strategic alliance partners. View Details

Keywords: Alliances; Research; Business Startups; Management Teams; Business Strategy; Biotechnology Industry; United States

June 2005 (Revised July 2006)
Background Note

Note on the Convergence Between Genomics & Information Technology

By: David B. Yoffie, Dharmesh M Mehta and Rachel Sha

Focuses on the convergence between the genomics and semiconductor industries, in particular organ printing, DNA computing, biomolecular sensory networks, and DNA microarrays. Explains what this newly converged world looks like based on current research and findings in... View Details

Keywords: Genetics; Information Technology; Business Model; Disruptive Innovation; Biotechnology Industry; Biotechnology Industry; Biotechnology Industry; Biotechnology Industry

Find at Harvard

December 1992 (Revised September 1996)
Case

ImmuLogic Pharmaceutical Corporation (Abridged)

By: Josh Lerner

ImmuLogic Pharmaceutical Corp., a development-stage biotechnology company, is considering making an initial offering of common stock. The rationales for and problems of high-technology start-ups are explored. The challenges posed by "windows" for public offerings are... View Details

Keywords: Decisions; Initial Public Offering; Entrepreneurship; Going Public; Business Startups; Biotechnology Industry; Biotechnology Industry; United States

November 2008
Case

Adnexus Therapeutics, Inc.: Considering the Exit

By: Vicki L. Sato and Rachel Gordon

Dr. John Mendlein, CEO of Adnexus Therapeutics Inc. (Adnexus), a private biotechnology company, must decide whether to pursue acquisition talks with Bristol-Myers Squibb (BMS) after a successful six-month collaboration or continue with Adnexus' planned IPO. View Details

Keywords: Mergers and Acquisitions; Decision Choices and Conditions; Entrepreneurship; Initial Public Offering; Corporate Strategy; Biotechnology Industry

June 1997 (Revised March 2001)
Case

Genset Initial Public Offering (A)

By: Paul A. Gompers and Jeffrey M. Anapolsky

Pascal Brandys, founder and CEO of Genset, must decide whether to take this young biotechnology company public. If so, should he do a dual offering in both France and the U.S.? The case also explores the business models in genomics research. View Details

Keywords: Business Model; Initial Public Offering; Genetics; Going Public; Management Teams; Biotechnology Industry; France; United States

January 2007
Background Note

Note on Biotech Business Development

By: Richard G. Hamermesh and Robert F. Higgins

Describes the business development process in biotechnology companies. Topics covered include: participants in the licensing process and their interests, the major steps in the licensing process, the terms that are part of most agreements, and the most contentious... View Details

Keywords: Agreements and Arrangements; Entrepreneurship; Intellectual Property; Biotechnology Industry

March 2016
Article

Environmental Demands and the Emergence of Social Structure: Technological Dynamism and Interorganizational Network Forms

By: Adam Tatarynowicz, Maxim Sytch and Ranjay Gulati

This study investigates the origins of variation in the structures of interorganizational networks across industries. We combine empirical analyses of existing interorganizational networks in six industries with an agent-based simulation model of network emergence.... View Details

Keywords: Interorganizatonal Relationships; Social Networks; Network Emergence; Interorganizational Networks; Information Technology; Networks; Organizational Structure; Social and Collaborative Networks; Social Media

Find at Harvard

November 1991 (Revised April 1994)
Case

Nucleon, Inc.

By: Gary P. Pisano

Nucleon is a small biotechnology company whose first potential product is about to enter clinical testing. Before Nucleon can begin clinical trials, however, its management must decide how and where to manufacture the product. Three options are being contemplated: 1)... View Details

Keywords: Factories, Labs, and Plants; Entrepreneurship; Health Testing and Trials; Rights; Product Development; Production; Partners and Partnerships; Research and Development; Biotechnology Industry

October 1992 (Revised November 1997)
Case

ImmuLogic Pharmaceutical Corporation (A): March 1991

By: Josh Lerner

ImmuLogic Pharmaceutical Corp., a development-stage biotechnology company, is considering making an initial offering of common stock. The diverse perspectives of the entrepreneur, venture capitalist, investment banker, and institutional investor are explored. Problems... View Details

Keywords: Decisions; Entrepreneurship; Venture Capital; Banks and Banking; Initial Public Offering; Going Public; Perspective; Valuation; Biotechnology Industry; Biotechnology Industry

August 2001
Case

Scios, Inc.

By: Regina E. Herzlinger

Scios, filled with distinguished scientists and experienced managers, nevertheless fails to clear the FDA Phase III process for an important biotechnology drug. This case asks the students to analyze the social costs and benefits of the regulatory process. View Details

Keywords: Governing Rules, Regulations, and Reforms; Health Care and Treatment; Cost Management; Cost vs Benefits; Social Issues; Pharmaceutical Industry; United States

Gary P. Pisano

Gary Pisano is the Harry E. Figgie, Jr. Professor of Business Administration at the Harvard Business School where he has been on the faculty since 1988. From 2018-2023, Pisano was Harvard Business School’s Senior Associate Dean for Faculty Promotion and... View Details

Keywords: biotechnology; biotechnology; biotechnology; biotechnology; biotechnology

←
5
6
…
24
25
→